Table 3.

LOAECs specific for each time interval and DNT endpoint and their serial dilutions tested in Phase 3

3 days	BPA	CPF	Lead	Methyl-Hg	PCB138	VA	(μM)
Synaptogenesis	28.96	37.1	0.007	0.26	5.93	420	LOAEC-syn
	14.48	18.55	0.004	0.13	2.97	210	LOAEC/2-syn
	7.24	9.28	0.002	0.07	1.48	105	LOAEC/4-syn
Neurite outgrowth	12.74	74.2	1.46	0.26	0.06	70	LOAEC-neu
	6.37	37.1	0.73	0.13	0.03	35	LOAEC/2-neu
	3.19	18.55	0.37	0.07	0.015	17.5	LOAEC/4-neu
BDNF levels	57.92	37.1	1.46	0.26	0.06	420	LOAEC-bdnf
	28.96	18.55	0.73	0.13	0.03	210	LOAEC/2-bdnf
	14.48	9.28	0.37	0.07	0.015	105	LOAEC/4-bdnf
14 days	BPA	CPF	Lead	Methyl-Hg	PCB138	VA	(μM)
Synaptogenesis	12.74	21.01	0.007	0.05	0.06	2.1	LOAEC-syn
	6.37	10.51	0.004	0.025	0.03	1.05	LOAEC/2-syn
Neurite outgrowth	12.74	74.2	1.46	0.13	11.86	420	LOAEC-neu
	6.37	37.1	0.73	0.07	5.93	210	LOAEC/2-neu
	3.19	18.55	0.37	0.03	2.97	105	LOAEC/4-neu
	1.59	9.28	0.18	0.016	1.48	52.5	LOAEC/8-neu
BDNF levels	12.74	37.1	1.46	0.13	3.53	210	LOAEC-bdnf
	6.37	18.55	0.73	0.07	1.77	105	LOAEC/2-bdnf
	3.19	9.28	0.37	0.03	0.88	52.5	LOAEC/4-bdnf